19,488 Shares in DexCom, Inc. $DXCM Purchased by Goodman Advisory Group LLC

Goodman Advisory Group LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 19,488 shares of the medical device company’s stock, valued at approximately $1,293,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Motley Fool Wealth Management LLC raised its stake in DexCom by 26.8% in the 4th quarter. Motley Fool Wealth Management LLC now owns 276,495 shares of the medical device company’s stock valued at $18,351,000 after acquiring an additional 58,495 shares during the period. Motley Fool Asset Management LLC increased its position in shares of DexCom by 24.5% during the fourth quarter. Motley Fool Asset Management LLC now owns 249,215 shares of the medical device company’s stock valued at $16,540,000 after buying an additional 48,999 shares during the period. Focus Partners Advisor Solutions LLC bought a new stake in shares of DexCom during the fourth quarter valued at about $868,000. Advocacy Wealth Management LLC bought a new stake in shares of DexCom during the fourth quarter valued at about $802,000. Finally, BLI Banque de Luxembourg Investments bought a new stake in shares of DexCom during the fourth quarter valued at about $3,354,000. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Jon Coleman sold 4,912 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total transaction of $358,576.00. Following the transaction, the executive vice president directly owned 100,361 shares in the company, valued at $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the transaction, the insider owned 382,482 shares in the company, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 42,694 shares of company stock valued at $3,029,267 over the last ninety days. Insiders own 0.28% of the company’s stock.

DexCom Stock Down 4.4%

Shares of NASDAQ DXCM opened at $74.77 on Thursday. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm’s 50 day simple moving average is $65.62 and its two-hundred day simple moving average is $67.40. The stock has a market capitalization of $28.85 billion, a P/E ratio of 31.95, a PEG ratio of 1.22 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business earned $0.32 earnings per share. The business’s quarterly revenue was up 15.0% on a year-over-year basis. As a group, analysts expect that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several analyst reports. Benchmark initiated coverage on DexCom in a research report on Monday, May 11th. They set a “buy” rating and a $77.00 price target on the stock. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Bank of America decreased their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. UBS Group set a $95.00 price objective on shares of DexCom in a research report on Wednesday. Finally, BTIG Research restated a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $84.29.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.